Please find enclosed outcome of board meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech's board approved unaudited standalone and consolidated financial results for Q1 FY26 (ended June 30, 2025). Standalone revenue from operations rose to Rs. 1,241.86 lakhs, up about 22.5% from Rs. 1,013.42 lakhs in Q1 FY25. Net profit (standalone) jumped sharply to Rs. 137.32 lakhs from Rs. 17.79 lakhs a year earlier, driven by lower finance costs and operating efficiencies. Consolidated PAT was Rs. 133.71 lakhs vs Rs. 16.64 lakhs YoY, with basic EPS of Rs. 0.74. The board also allotted 13,33,332 equity shares at Rs. 45 each (Rs. 35 premium) on conversion of warrants to two public entities, bringing in Rs. 4.5 crore and raising total share capital to Rs. 21.33 crore (2.13 crore shares). Statutory auditor P. Murali & Co. issued an unqualified review report on both standalone and consolidated results.
Strong year-on-year profit growth signals improving operational efficiency and easing finance costs, though revenue base remains modest. The warrant-driven equity dilution modestly expands the share count; existing investors should note EPS impact from a higher share base going forward.